1. Freeman_et_al-2016-Liver_International                                                                                                                   The use of generic DAAs for hepatitis C treatment
2. HCV treatment via primary care providers                                                                                                                               A study that evaluates the efficacy and safety of primary care driven HCV treatment given the advent of directly acting antiviral therapy.
3. E. B. Cunningham, Tanya L. Applegate et al, Mixed HCV infection and reinfection in people who inject drugs—impact on therapy_Mar 2015
   A Review characterizing the epidemiology and natural history of mixed infection and reinfection among PWID, methodologies for detection, the potential implications for HCV treatment and considerations for the design of future studies by E. B. Cunningham, Tanya L. Applegate et al published on 17 Mar, 2015.
4. Mehdi Najafzadeh, PhD; Karin Andersson, MD et al, Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus_Mar 2015
   An article studying the cost-effectiveness of usual regimens of treatments for HCV compared with sofosbuvir–ribavirin–PEG and 3 PEG-free regimens: sofosbuvir–simeprevir, sofosbuvir–daclatasvir,and sofosbuvir–ledipasvir and how they are cost effective for genotype 1 and probably 3, but not genotype 2 by Mehdi Najafzadeh, PhD; Karin Andersson, MD et al published on  17 Mar, 2015.
5. Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV_CROI 2015
   A study on the impact of SVR on liver decompensation and hepatic fibrosis markers in HIV published in Feb 2015.
6. Hepatitis C The Lancet_Feb 2015
   Understanding Hepatitis C – virology, epidemiology, immunology, diagnosis, treatment published in the Lancet, Feb 2015.
7. Nikolien van de Ven, Joe Fortunak et al, Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus_2014
   An article that aimed to estimate minimum costs of DAA treatment and associated diagnostic monitoring published in Hepatology in 2014.
8. David P. Wilsona, Braedon Donald et al, The cost-effectiveness of harm reduction_Nov 2014
   This article discusses the evidence of effectiveness of the packages of harm reduction services and their cost-effectiveness with respect to HIV-related outcomes as well as estimate resources required to meet global and regional coverage targets and was accepted by International Journal of Drug Policy in Nov 2014.
9. Judith I. Tsui,MD, MPH; Jennifer L. Evans, MS et al, Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users_Oct 2014
   JAMA Intern Med’s article published in Oct, 2014 that investigates whether opioid agonist therapy was associated with a lower incidence of HCV infection in a cohort of young adult PWID.
10. Bethany White, Gregory J Dore, et al, Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study_Sep 2014
    MJA’s article that estimates HCV incidence and identifies associated risk and protective factors among PWID in New South Wales published in Sep 2014.
11. Seonaid Nolan, Viviane Dias Lima et al, The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users_Jul 2014
    A report that determines the relationship between methadone maintenance therapy (MMT) and HCV seroconversion among people who use drugs published in Addiction in Jul, 2014.
12. Andrew Hill, Saye Khoo et al, Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment access Programs in Developing Countries _2014
    Presentation on how large scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible with minimum target prices of $100–$250 per 12-week treatment course, and how this could make widespread access to HCV treatment a realistic goal by Andrew Hill, Saye Khoo et al published on Feb 13, 2014.
13. Andrew Hill, Saye Khoo et al, Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment access Programs in Developing Countries _2014
    Major article on how large scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100–$250 per 12-week treatment course, and how this could make widespread access to HCV treatment a realistic goal by Andrew Hill, Saye Khoo et al published on Feb 13, 2014.
14. Liesl M. Hagan, Paul Root Wolpe et al, Treatment as prevention and cure towards global eradication of hepatitis C virus_2013
    A review of how the availability of curative drugs for HCV engenders the ethical necessity to deploy treatment in pursuit of global eradication and an HCV-free generation by Liesl M. Hagan, Paul Root Wolpe et al published in Dec, 2013.
15. Barbara Milani, Sara Gaspani, Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating Hepatitis C_2013
    An article on how besides adding pegylated interferon alpha to the essential medicines list of WHO in Jul, 2013, more progressive WHO guidance is required to expand access to treatment in developing countries by Barbara Milani, Sara Gaspani published on 14th Nov, 2013.
16. Georgina J. MacArthur, Eva van Velzen et al, Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness_Jul 2013
    An article reviewing the reviews regarding the effectiveness of harm reduction interventions in relation to HIV transmission, HCV transmission and injecting risk behaviour (IRB) published in the International Journal of Drug Policy.
17. Leandro Sereno, Fabio Mesquita et al, Epidemiology, Responses, and Way Forward: The Silent Epidemic of Viral Hepatitis and HIV Co-infection in Vietnam_2012
    An article highlighting the importance of viral hepatitis in the Vietnam population, as well as, in the group of people living with HIV (PLHIV) and stressing the need to develop policies for diagnosis and treatment of chronic HBV and HCV infections to prevent clinical progression by Leandro Sereno, Fabio Mesquita et al published on 24th Jul, 2012.
18. Nicolas Durier, Chi Nguyen et al, Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam_2012
    A study conducted in Vietnam projecting that treatment of HCV for people who inject drugs will have a preventative herd effect in addition to curing patients in need for therapy, achieving a substantial reduction in HCV transmission and prevalance by Nicolas Durier, Chi Nguyen et al published on April 12, 2012.
19. Nathan Ford, Kasha Singh et al, Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS_2012
    An article by Nathan Ford, Kasha Singh et al highlighting how many of the obstacles to widespread access to HCV treatment can be addressed by drawing lessons from the rolling out of the HIV treatment in the last decade published on Mar 19, 2012.
20. Nathan Ford, Catherine Kirby et al, Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis_2012
    A systematic review and meta-analysis of studies of HCV treatment programmes in low- and middle-income countries to identify factors associated with successful outcomes and how the outcome of HCV treatment in low/middle income countries were the same as in high-income countries by Nathan Ford, Catherine Kirby et al published in 2012.
21. Holly Hagan, Enrique R. Pouget et al, A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs_Jul 2011
    An article that determines that HCV infection can be prevented in PWID published in The Journal of Infectious Diseases in July 2011.
22. Katy M. E. Turner, Sharon Hutchinson et al, The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence_2011
    An article published in Addiction in 2011 that investigates whether opiate substitution therapy (OST) and needle and syringe programmes (NSP) can reduce HCV transmission among people who inject drugs.
23. D. Lavanchy, Evolving epidemiology of hepatitis C virus_2010
    A review on the evolving epidemiology of HCV stressing the need to complete the assesment of the national HCV prevalence and transmission modes and developing a safe and efficient HCV vaccine by D. Lavanchy published on 22nd Nov, 2010.
24. Charlotte Van Den Berg, Colette Smit et al, Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users_2007
    An article published in Addiction in 2007 that investigates the impact of harm-reduction programmes on HCV incidence among ever-injecting drug users (DU) from the Amsterdam Cohort Studies (ACS).

The contents of this section are taken, as it is available in its original form to inform communities affected by Hepatitis C virus for the best use of the information to benefit the community. The ownership of the materials lies with original authors and APN+ would like to request all those who cite these information to inform and acknowledge original authors.